Effects of either Sitagliptin or Pioglitazone Addition on Metformin in Patients with Uncontrolled Type 2 Diabetic Mellitus
Authors/Creators
- 1. Post Graduate Student, Department of Pharmacology, Rama Medical College Hospital and Research Centre, Kanpur, U.P.
- 2. Professor and Head of Department, Department of Pharmacology, Rama Medical College Hospital and Research Centre, Kanpur, U.P.
- 3. Professor, Department of Pharmacology, Rama Medical College Hospital and Research Centre, Kanpur, U.P.
- 4. Associate Professor, Department of Pharmacology, Rama Medical College Hospital and Research Centre, Kanpur, U.P.
- 5. Professor and Head, Department of General Medicine, Rama Medical College Hospital and Research Centre, Kanpur, U.P.
Description
Objective: Compare and study the use of metformin and DPP-4 inhibitors in conjunction with currently used combination treatments. Materials and Methods: In this 16-week study, sitagliptin and pioglitazone were compared as add-on treatments for type 2 diabetes mellitus patients whose condition was not sufficiently controlled by metformin alone. In addition to metformin, 52 patients were randomly assigned to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2). Change in HbA1c served as the main efficacy end objective. Changes in body weight, lipid profile, and fasting plasma glucose (FPG) were considered secondary end objectives. HbA1c significantly dropped in both groups. Results: In neither group did the mean FPG reductions differ significantly from one another. In group 1, the mean body weight and body mass index significantly decreased, while the same variables significantly increased in group 2. High density lipoprotein (HDL-C) and triglyceride levels significantly dropped in both therapy groups, according to the reports. Conclusion: The drug was well tolerated and did not cause any instances of hypoglycemia. It was determined that pioglitazone was not as effective or well tolerated as sitagliptin when added to metformin.
Abstract (English)
Objective: Compare and study the use of metformin and DPP-4 inhibitors in conjunction with currently used combination treatments. Materials and Methods: In this 16-week study, sitagliptin and pioglitazone were compared as add-on treatments for type 2 diabetes mellitus patients whose condition was not sufficiently controlled by metformin alone. In addition to metformin, 52 patients were randomly assigned to receive either sitagliptin 100 mg (group 1) or pioglitazone 30 mg (group 2). Change in HbA1c served as the main efficacy end objective. Changes in body weight, lipid profile, and fasting plasma glucose (FPG) were considered secondary end objectives. HbA1c significantly dropped in both groups. Results: In neither group did the mean FPG reductions differ significantly from one another. In group 1, the mean body weight and body mass index significantly decreased, while the same variables significantly increased in group 2. High density lipoprotein (HDL-C) and triglyceride levels significantly dropped in both therapy groups, according to the reports. Conclusion: The drug was well tolerated and did not cause any instances of hypoglycemia. It was determined that pioglitazone was not as effective or well tolerated as sitagliptin when added to metformin.
Files
IJPCR,Vol14,Issue10,Article95.pdf
Files
(314.0 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:ff4cb3d18e442f376d33df595d42f21c
|
314.0 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-10-20
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue10,Article95.pdf
- Development Status
- Active
References
- 1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047‑53. 2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005‑12. 3. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs 2006; 66: 1863‑77. 4. Mohan V, Joshi SR. The Rosiglitazone Controversy: The Indian Perspective. J Assoc Physicians India 2007; 55:477‑80. 5. Gallwitz B. Review of sitagliptin phosphate: A novel treatment for type 2 diabetes. Vasc Health Risk Manag 2007; 3:203‑10. 6. Bradley C, Lewis KS. Measures of psychological well‑being and treatment satisfaction developed from the responses of people with tablet treated diabetes. Diabet Med 1990; 7:445‑51. 7. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007; 125:217‑30. 8. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: Acomparative study between Asians and Caucasians. Maturitas 2010; 65:315‑9. 9. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Sitagliptin study 020 group. Efficacy and safety of the dipeptidyl peptidase‑4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29:2638‑43. 10. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Sitagliptin study 035 group. Efficacy and safety of the dipeptidyl peptidase‑4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9:733‑45. 11. Scott R, Loeys T, Davies MJ, Engel SS. Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10:959‑69. 12. Ludvik B, Daniela L. Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. Wien Klin Wochenschr 2011; 123:235‑40. 13. Reasner C, Olansky L, Seck TL, Williams‑Herman DE, Chen M, Terranella L, et al. The effect of initial therapy with the fixed‑dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13:644‑52. 14. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22:1395‑409. 15. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24‑week, randomized, double‑blind study. Diabetes Obes Metab 2008; 10:82‑90. 16. Matthews DR, Charbonnel BH, Hanefeld M. Long‑term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev 2005; 21:167‑74. 17. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24:537‑50. 18. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Sitagliptin study 024 group. Efficacy and safety of the dipeptidyl peptidase‑4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double blind, non-inferiority study. Diabetes Obes Metab 2007; 9:194‑205. 19. Bourdel‑Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (Minneap) 2011; 39:7‑21. 20. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13:366‑73. 21. Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RG, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006; 3:39‑44. 22. Pfützner A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, Müller J, et al.PIOfix‑Study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011; 13:637‑43. 23. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3‑year, randomized, comparator-controlled study in the US. Drug Saf 2009; 32:787‑800. 24. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase‑4 inhibitors: Similarities and differences. Drugs 2011; 71:1441‑67. 25. Sitagliptin (marketed as Januvia and Janumet) -acute pancreatitis FDA safety information. [Online]. 2009 September 25. 26. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, et al. Cost‑effectiveness of sitagliptin based treatment regimens in European patients with type 2 diabetes and haemoglobinA1c above target on metformin monotherapy. Diabetes Obes Metab 2008; 10:43‑55.